Pimozide (sold under the brand name Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special neurologic indications for Tourette syndrome and resistant tics. The side effects include akathisia, tardive dyskinesia, and, more rarely, neuroleptic malignant syndrome and prolongation of the QT interval.
In the last several years, global market of Pimozide developed slowly, with an average growth rate of -2.48%. In 2017, global revenue of Pimozide is nearly 13 M USD; the actual sales are about 10210 K Unit.
The global average price of Pimozide is in the increasing trend, from 1.13 USD/Unit in 2013 to 1.19 USD/Unit in 2017. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Pimozide includes 1Mg, 2Mg, 4Mg, and the proportion of 2Mg in 2017 is about 53%.
Pimozide is widely used in hospitals, drugstores and other places. The most proportion of Pimozide is used for hospitals in 2017 is 54%.
North America and Europe are the two largest consumption place, with a similar consumption market share nearly 40% in 2017.
Market competition is not intense. Teva, Par Pharmaceutical, Johnson & Johnson, Eumedica and Pharmascience, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.